Oncology bispecific antibody trial starts

RecordSTO-8QZ64SZQ5Z-CRF55E32JE-82C8K6

China · 2021

Oncology bispecific antibody trial starts in China were 41 in 2021 (ClinicalTrials.gov).

Publisher: ClinicalTrials.gov
Authority tier: T1 Official
Report: ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China
Locator: totalCount field of the API response. Query: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China.
Retrieved: 27 Sep 2026
Status: Verified

What the source says

{"totalCount":41,"studies":[
ClinicalTrials.gov (U.S. National Library of Medicine), ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China, totalCount field of the API response. Query: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China.

Checked: the figure 41 is stated in this passage. If it does not match, the extraction is wrong and we want to know.

Cite this figure

APA

ClinicalTrials.gov (U.S. National Library of Medicine). (2021). ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab%20OR%20SMT112%20OR%20PF-08634404%20OR%20AK104%20OR%20odronextamab%20OR%20etentamig%20OR%20ABBV-383&query.cond=cancer%20OR%20tumor%20OR%20neoplasm%20OR%20carcinoma%20OR%20lymphoma%20OR%20leukemia%20OR%20myeloma%20OR%20malignancy%20OR%20%22solid%20tumor%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_8QZ64SZQ5ZCRF55E32JE82C8K6

Other formats: MLA, Chicago, BibTeX

MLA: ClinicalTrials.gov (U.S. National Library of Medicine). "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China." 2021, https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab%20OR%20SMT112%20OR%20PF-08634404%20OR%20AK104%20OR%20odronextamab%20OR%20etentamig%20OR%20ABBV-383&query.cond=cancer%20OR%20tumor%20OR%20neoplasm%20OR%20carcinoma%20OR%20lymphoma%20OR%20leukemia%20OR%20myeloma%20OR%20malignancy%20OR%20%22solid%20tumor%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId. Accessed 27 Sept. 2026 via StatOrigin, https://statorigin.org/stat/stat_8QZ64SZQ5ZCRF55E32JE82C8K6.
Chicago: ClinicalTrials.gov (U.S. National Library of Medicine). "ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China." 2021. https://clinicaltrials.gov/api/v2/studies?query.term=bispecific%20OR%20ivonescimab%20OR%20cadonilimab%20OR%20AK112%20OR%20PM8002%20OR%20BNT327%20OR%20pumitamig%20OR%20SSGJ-707%20OR%20zanidatamab%20OR%20amivantamab%20OR%20tarlatamab%20OR%20epcoritamab%20OR%20glofitamab%20OR%20mosunetuzumab%20OR%20teclistamab%20OR%20talquetamab%20OR%20elranatamab%20OR%20linvoseltamab%20OR%20SMT112%20OR%20PF-08634404%20OR%20AK104%20OR%20odronextamab%20OR%20etentamig%20OR%20ABBV-383&query.cond=cancer%20OR%20tumor%20OR%20neoplasm%20OR%20carcinoma%20OR%20lymphoma%20OR%20leukemia%20OR%20myeloma%20OR%20malignancy%20OR%20%22solid%20tumor%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22China%22&countTotal=true&pageSize=1&fields=NCTId. Accessed September 27, 2026. Cited from StatOrigin, https://statorigin.org/stat/stat_8QZ64SZQ5ZCRF55E32JE82C8K6.
BibTeX: @misc{clinicaltrialsgo2021ctgov82c8k6, author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}}, title = {ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China}, year = {2021}, howpublished = {StatOrigin, https://statorigin.org}, url = {https://statorigin.org/stat/stat_8QZ64SZQ5ZCRF55E32JE82C8K6}, note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.term=bispecific\%20OR\%20ivonescimab\%20OR\%20cadonilimab\%20OR\%20AK112\%20OR\%20PM8002\%20OR\%20BNT327\%20OR\%20pumitamig\%20OR\%20SSGJ-707\%20OR\%20zanidatamab\%20OR\%20amivantamab\%20OR\%20tarlatamab\%20OR\%20epcoritamab\%20OR\%20glofitamab\%20OR\%20mosunetuzumab\%20OR\%20teclistamab\%20OR\%20talquetamab\%20OR\%20elranatamab\%20OR\%20linvoseltamab\%20OR\%20SMT112\%20OR\%20PF-08634404\%20OR\%20AK104\%20OR\%20odronextamab\%20OR\%20etentamig\%20OR\%20ABBV-383\&query.cond=cancer\%20OR\%20tumor\%20OR\%20neoplasm\%20OR\%20carcinoma\%20OR\%20lymphoma\%20OR\%20leukemia\%20OR\%20myeloma\%20OR\%20malignancy\%20OR\%20\%22solid\%20tumor\%22\&filter.advanced=AREA\%5BStudyType\%5DINTERVENTIONAL\%20AND\%20AREA\%5BStartDate\%5DRANGE\%5B2021-01-01\%2C2021-12-31\%5D\%20AND\%20AREA\%5BLocationCountry\%5D\%22China\%22\&countTotal=true\&pageSize=1\&fields=NCTId. Accessed September 27, 2026.} }

Data published under CC BY 4.0. The citation credits the original publisher and links to this permanent record.

Provenance and verification

Everything needed to check this number yourself, without taking our word for it.

Primary source

Publisher: ClinicalTrials.gov (U.S. National Library of Medicine) · homepage ↗
Authority tier: Tier 1 · Multilateral Official
Report: ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China
Type: Dataset
Published: —
Locator: totalCount field of the API response. Query: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China.
Retrieved: 27 September 2026
Link status: Reachable (HTTP 200)
Report licence: Public domain

Verification

Status: Verified
Review protocol: pipeline:ctgov-api-totalcount-verified
Checked on: 27 September 2026
Last revision: 27 September 2026
Permanent URL: /stat/stat_8QZ64SZQ5ZCRF55E32JE82C8K6

Same indicator, other countries

2021 figures for the same indicator, ranked highest first.

Country or region	Value	Source	Details
Global	104	ClinicalTrials.gov	Open record
United States	58	ClinicalTrials.gov	Open record

This figure in context

Cited in

Oncology bispecific antibodies: PD-(L)1 x VEGF drugs lead a China-driven boom

Go further

Record last modified 27 September 2026. Value type: actual. Update cadence: irregular. This page is permanently addressable at statorigin.org/stat/stat_8QZ64SZQ5ZCRF55E32JE82C8K6.